Finoriq research workspace
Acrivon Therapeutics, Inc. (ACRV) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Acrivon Therapeutics, Inc. (ACRV).
Company Snapshot
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
- Company
- Acrivon Therapeutics, Inc. (ACRV)
- Ticker
- ACRV
- Market Cap
- $74M
- Latest Price
- $1.73
- Industry
- Biotech & Pharma
Acrivon Therapeutics, Inc. (ACRV) Recent Insider Transactions
Recent market insider transaction records indexed for Acrivon Therapeutics, Inc. (ACRV).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| Blume-Jensen PeterPresident and CEO | P | Acquired | $82,124 | 2026-01-14 |
| Masson KristinaEVP - Business Operations | P | Acquired | $82,124 | 2026-01-14 |
| Levy Adam D.Chief Financial Officer | P | Acquired | $14,999 | 2026-01-14 |
| Devroe EricChief Operating Officer | P | Acquired | $17,218 | 2026-01-13 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.